---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-018424"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-14T23:33:21.170998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma announces $65M PIPE and positive Phase 3 mavorixafor data in WHIM syndrome

## Summary
- 42.8M shares/pre-funded warrants priced at $1.52, raising $65M gross; expected close May 18, 2023.
- Phase 3 4WHIM trial: mavorixafor reduced annualized infection rate by ~60% vs placebo (p<0.01).
- Severe (Grade≥3) infections cut by 75%; mean infection duration reduced >70% (2 weeks vs 7 weeks on placebo).
- NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023 after pre-NDA meeting with FDA.
- Cash runway extended into Q4 2024, excluding potential priority review voucher proceeds.

## SEC filing metadata
- accession: 0001628280-23-018424
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828023018424/0001628280-23-018424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828023018424/xfor-20230515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-018424
- JSON: https://secwatch.observer/filing/0001628280-23-018424.json
- Plain text: https://secwatch.observer/filing/0001628280-23-018424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.